Maze Therapeutics (NASDAQ:MAZE) Releases Quarterly Earnings Results, Beats Expectations By $0.08 EPS

Maze Therapeutics (NASDAQ:MAZE) posted its quarterly earnings data on Thursday. The company reported ($0.66) earnings per share for the quarter, beating the consensus estimate of ($0.74) by $0.08, Zacks reports.

Maze Therapeutics Stock Performance

MAZE traded down $0.64 on Thursday, hitting $29.63. 276,063 shares of the company were exchanged, compared to its average volume of 322,400. The stock’s fifty day moving average is $25.26 and its 200-day moving average is $16.98. Maze Therapeutics has a 12 month low of $6.71 and a 12 month high of $34.29.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the company. JPMorgan Chase & Co. increased their price objective on Maze Therapeutics from $27.00 to $37.00 and gave the stock an “overweight” rating in a research report on Monday, September 29th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Maze Therapeutics in a research note on Wednesday, October 8th. Wall Street Zen raised Maze Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 16th. BTIG Research increased their price objective on Maze Therapeutics from $30.00 to $37.00 and gave the company a “buy” rating in a report on Friday, September 12th. Finally, HC Wainwright reissued a “buy” rating and set a $50.00 price objective on shares of Maze Therapeutics in a report on Thursday, September 18th. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $33.83.

Insider Activity at Maze Therapeutics

In related news, Director Richard H. Scheller sold 20,744 shares of the firm’s stock in a transaction on Monday, September 15th. The stock was sold at an average price of $22.37, for a total transaction of $464,043.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in Maze Therapeutics in the 1st quarter worth $57,000. Goldman Sachs Group Inc. acquired a new stake in Maze Therapeutics in the first quarter valued at approximately $145,000. Rhumbline Advisers purchased a new position in shares of Maze Therapeutics during the first quarter worth $80,000. Geode Capital Management LLC raised its holdings in shares of Maze Therapeutics by 8.8% during the second quarter. Geode Capital Management LLC now owns 231,237 shares of the company’s stock worth $2,838,000 after purchasing an additional 18,773 shares during the last quarter. Finally, Legal & General Group Plc grew its position in shares of Maze Therapeutics by 387.0% in the second quarter. Legal & General Group Plc now owns 4,242 shares of the company’s stock valued at $52,000 after purchasing an additional 3,371 shares during the period.

About Maze Therapeutics

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.